Kenya Premises Licensing and GSDP: Risk-Based Inspection and Traceability

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

Content verified on: October 30, 2026

1. Key takeaways

  • On October 30, 2025, PPB adopted a risk-based inspection framework anchored on WHO standards, applying equally to wholesalers, community pharmacies and hospital pharmacies (this framework information comes from public reporting and is a practical estimate).
  • Kenya fully implements Good Storage and Distribution Practice (GSDP); warehousing and distribution operations must build and maintain a system under this practice.
  • PPB is pursuing WHO Maturity Level 3 (ML3) and preparing for a WHO Global Benchmarking Tool (GBT) evaluation in September 2026.
  • Enforcement intensity is rising: intelligence-led operations have arrested more than 95 illegal operators, and regulatory and disciplinary measures have been taken against 22 wholesale businesses suspected of supplying illegal outlets; legacy unregistered products have been removed from the formal register (the above figures come from public reporting and are a practical estimate).
  • Traceability connection: the National Authentication and Traceability System together with Practice360 and Facility360 went live on August 3, 2026, with an onboarding deadline of October 31, 2026; those who fail to onboard will not be issued 2027 practising and premises licences.

2. Legal basis

InstrumentReference / numberDate made / effectiveProvisionsPoints relevant to this article
Guidelines for Registration of Medical Devices EstablishmentsPRA/LPP/GUD/072—Whole documentBaseline requirements for establishment registration and premises qualification; PPB conducts document review and on-site inspection
Guidelines for Registration of Medical Devices including In-Vitro DiagnosticsHPT/PER/HTR/GUD/011, Rev.02Effective January 31, 2022; review due January 1, 2027Sections 2.11, 2.13Annual retention and the duty to stop import and supply after market exit, forming part of the continuing compliance obligations of premises
Pharmacy and Poisons ActCap. 244, Laws of KenyaEnacted 1957Sections 9A, 27Practising licence and wholesaler licence, providing the parent-law basis for premises licensing
The Health Act, 2017No. 21 of 2017Assented June 21, 2017; commenced July 7, 2017Sections 62–67Functions, conditions, licensing and standards of the single regulator for health products and technologies
Standards ActCap. 496——Functions of the Kenya Bureau of Standards (KEBS) and the legal basis of the PVoC programme, connecting with premises checks on the import side

3. Expert insights

Insight 1: Risk-based inspection shifts inspection resources from uniform effort to risk weighting

A risk-based inspection framework anchored on WHO standards means that inspection frequency and depth will be linked to the risk class of the products a business handles and to its compliance history. GRZAN judges that wholesalers carrying Class C/D devices such as orthopaedic implants or cardiovascular intervention devices will face noticeably deeper sampling than entities handling only Class A consumables. Businesses should recalibrate their self-inspection frequency accordingly rather than keeping a uniform annual self-check rhythm across the whole portfolio.

Insight 2: The GSDP review focus is shifting from having documents to having data

The quality manuals, procedures and declarations required by the guideline system are static evidence; once risk-based inspection combines with GSDP, the review focus moves to dynamic data — continuous temperature and humidity monitoring records, closed-loop handling of deviations and excursions, batch-level receipt-and-issue ledgers, and transport validation and excursion records. GRZAN recommends organising warehouse data as an evidence chain searchable by batch number, because once the traceability system is live, batch-level data becomes the direct handle inspectors pull.

Insight 3: Enforcement data show compliance responsibility extending upstream along the supply chain

Measures against 22 wholesale businesses suspected of supplying illegal outlets, together with the arrest of more than 95 illegal operators, point not at the end outlets but at their upstream suppliers. GRZAN notes that wholesalers must therefore substantively verify and document the qualifications of their downstream customers; claiming ignorance is not a defence. At the same time, legacy unregistered products have been removed from the register, leaving no room for supply arrangements that rely on historical legacy certificates.

Insight 4: Premises licensing and traceability onboarding are now hard-linked

The onboarding deadline is October 31, 2026, expressly non-extendable and non-negotiable, and those who fail to onboard will not be issued 2027 practising and premises licences. GRZAN judges that for establishments, the priority of traceability onboarding should now equal that of premises licence renewal itself, because the two have been bound together procedurally. The detailed onboarding requirements and interface specifications must follow PPB’s subsequent formal notices (a practical estimate).

4. Practical recommendations

  1. Run a risk self-assessment. GRZAN recommends self-assessing the premises against the A/B/C/D classes of the products handled, and setting self-inspection frequency and sampling ratios from that result.
  2. Upgrade temperature and humidity monitoring. Establish continuous monitoring with excursion alarms; every excursion needs a record, an assessment and a disposition conclusion, closing the loop.
  3. Keep batch-level ledgers. Refine receipt-and-issue ledgers to batch number so that forward and backward traceability by batch works live during an inspection.
  4. Verify downstream qualifications. Build a customer-qualification verification checklist with documented evidence, and stop supplying unlicensed outlets without exception.
  5. Complete traceability onboarding. Finish system onboarding before October 31, 2026 and keep the onboarding confirmation.
  6. Align with WHO standards. Bring internal inspection checklists toward the relevant WHO standards, leaving headroom for the inspection upgrades expected after PPB’s push to ML3 and the September 2026 GBT evaluation.

5. Verification checklist

  • □ Has a premises risk self-assessment been completed against the risk classes of the products handled?
  • □ Is warehouse temperature and humidity continuously monitored, with closed-loop excursion records retained?
  • □ Are receipt-and-issue ledgers refined to batch number and capable of two-way traceability?
  • □ Is a downstream customer-qualification checklist with documented evidence in place?
  • □ Was traceability system onboarding completed before October 31, 2026 with a confirmation obtained?
  • □ Has a GSDP item-by-item compliance self-check of the premises been completed?
  • □ Are separate reminders set for the expiry dates of the establishment registration certificate and the premises licence?
  • □ Is a remediation window reserved for stricter inspections after WHO ML3 and the September 2026 GBT evaluation?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on jurisdictions such as Kenya, Nigeria, South Africa and Egypt and runs a verification mechanism built on primary regulatory sources: every regulatory conclusion it publishes relies solely on official gazettes, the original texts of regulator guidelines and public legal databases, each marked with a verification date. Any figure, timeline or amount that cannot be located in an official source is flagged as a practical estimate rather than an assumption.

GRZAN services cover: market access strategy and risk-classification assessment; preparation and review of registration dossiers (CSDT, STED and CTD formats); selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance coaching; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; regulatory intelligence subscriptions and corporate compliance ledgers.

For a Kenya market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail